Items Tagged ‘advanced’

October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab


October 11th, 2016

Epacadostat Plus Keytruda® Appears Effective in Melanoma

By

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery, melanoma has a high cure rate. However, once melanoma invades deeper tissues or spreads from its […]

View full entry

Tags: advanced, Epacadostat, keytruda, Melanoma, mole, News, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


September 20th, 2016

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

By

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination being considered as a new standard of care for patients with this disease. These results were recently published in the Lancet Oncology. Melanoma is a […]

View full entry

Tags: advanced, BRAF V600, cobimetinib, combination, Melanoma, metastatic, News, Stage III Melanoma, Stage IV Melanoma, vemurafenib


September 14th, 2016

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug that is planned for use to treat a serious or life-threatening disease […]

View full entry

Tags: advanced, General Lung Cancer, KEYNOTE-024, Lung Cancer, Lung Cancer - Non-Small Cell, Merck, News, nsclc, pembrolizumab, Stages IIIB-IV Lung Cancer - Non-Small Cell


September 13th, 2016

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer

By

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled trial of its kind. As many as 30% of all patients with NSCLC will present with or develop brain metastases. There is currently a routine practice […]

View full entry

Tags: advanced, brain metastases, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, QUARTZ, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, surgery, WBRT


September 7th, 2016

Keytruda® Approved for Advanced Head and Neck Cancer

By

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck squamous cell cancer […]

View full entry

Tags: advanced, fda, General Head and Neck Cancer, Head and Neck Cancer, keytruda, metastatic, News, pembrolizumab


August 22nd, 2016

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment

By

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed advanced ovarian cancer. While the standard of care in this setting is primary cytoreductive surgery (PCS) followed […]

View full entry

Tags: advanced, asco, cytoreductive surgery, epithelial, metastatic, NACT, News, Ovarian Cancer, SGO, Stage II-IV Ovarian Cancer


July 21st, 2016

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

By

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Advanced melanoma refers to skin […]

View full entry

Tags: 2016, advanced, asco, BRAFV600E/K mutation, COMBI-d trial, dabrafenib, kinase inhibitors, mekinist, Melanoma, News, Stage IV Melanoma, Taflinar


June 28th, 2016

Novel Antibody Improves Survival in Advanced Stomach Cancer

By

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Stomach cancer, […]

View full entry

Tags: 2016, advanced, asco, Gastric Cancer, GEJ cancer, IMAB362, News, Stages III-IV Gastric Cancer, stomach cancer


June 8th, 2016

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer

By

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Bladder cancer will be diagnosed in approximately 77,000 people in […]

View full entry

Tags: advanced, atezolizumab, Bladder Cancer, elderly, immunotherapy Tecentriq, News, smokers, Stage IV/Metastatic Bladder Cancer, urothlial carcinoma


June 8th, 2016

Long-Lasting Responses Achieved with Keytruda® in Advanced Head and Neck Cancer

By

Treatment with the immune-stimulating agent, Keytruda® (pembrolizumab), provides impressive long-term outcomes for some patients with metastatic or recurrent head and neck cancer. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Globally, head and neck cancer comprises the seventh most common type of cancer with an […]

View full entry

Tags: advanced, ASCO 2016, General Head and Neck Cancer, Head and Neck Cancer, HNSCC, KEYNOTE-012, keytruda, metastatic, News, perbrolizumab, squamous cell cancer


December 2nd, 2015

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

By

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The indication for this expanded approval specifies that Opdivo can be used for treatment […]

View full entry

Tags: advanced, CheckMate -066 trial, Melanoma, metastatic, News, opdivo, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


November 10th, 2015

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer

By

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published in the New England Journal of Medicine while simultaneously being presented at the 2015 European Cancer Congress. Lung cancer remains […]

View full entry

Tags: advanced, docetaxel, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-squamous, nsclc, opdivo, PD-1 inhibitor, Recurrent Lung Cancer - Non-Small Cell, squamous


November 3rd, 2015

Onivyde Approved for Pancreatic Cancer

By

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The approval is indicated for patients with pancreatic cancer that has spread to distant sites in the body who have received prior treatment with the chemotherapy agent, […]

View full entry

Tags: advanced, fluorouracil, irinotecan liposome injection, leucovorin, News, Onivyde, Pancreatic Cancer, Stage IV Pancreatic Cancer


November 2nd, 2015

Yondelis® Approved for Treatment of Soft Tissue Sarcoma

By

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The approval of Yondelis is for patients whose cancer is not able to be removed by surgery and/or has spread to distant sites in the body. This treatment is approved […]

View full entry

Tags: advanced, leimyosarcoma, liposarcoma, News, Sarcoma, Soft Tissue Sarcomas, trabectedin, yondelis